Table 1 The epidemiology of HSCT, dc-SSc control group A, and male+Scl70+ dc-SSc control group B showed the prevalence of risk factors for progressive SSc in all three cohorts at baseline
Baseline DNSS visit | HSCT | all dcSSccontrols A | p | dcSSc+ Scl70+ male controls B | p | |
|---|---|---|---|---|---|---|
Patient number (N) | 80 | 1513 | --- | 240 | --- | |
Age at SSc diagnosis (mean ± SD) | 38.3 ± 11.7 | 46.6 ± 14.2 | <0.001 | 46.5 ± 12.1 | <0.001 | |
Age at HSCT | 43.0 ± 10.9 | |||||
Time diagnosis to HSCT | 4.1 ± 4.8 | |||||
Age at DNSS baseline | 44.3 ± 10.8 | 53.3 ± 13.6 | <0.001 | 50.3 ± 12.0 | 0.002 | |
Clinical course | Limited | 10 (12.5) | 0 | 0 | ||
diffuse | 69 (86.3) | 1433 (94.7) | 240 (100.0) | |||
other | 1 ( 1.3) | 0 | 0 | |||
Male gender | 35 (43.8) | 406 (26.8) | 0.003 | 240 (100.0) | ||
ANA positive (>1:80, N (%)) | 73 (91.3) | 1236 (81.7) | 1.0 | 240 (100.0) | ||
Anti Scl70 / topoisomerase | 57 (71.3) | 812 (53.7) | 0.034 | 240 (100.0) | ||
Body mass index (kg/m2) | 22.8 ± 4.2 | 24.3 ± 4.6 | 0.015 | 25.0 ± 4.5 | 0.001 | |